Trial Profile
Study to Evaluate Efficacy and Safety of ADVATE in the Treatment of Previously Treated Patients With Hemophilia A
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Baxalta; Baxter Healthcare Corporation
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.